AchieveCE Reducing the Risk of ADHD
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and criminal behavior. This activity discusses how to reduce the risk of ADHD with PTBM and drugs approved by the FDA for treatment of ADHD.
Cost: $24.00Add to cart
Key Features
-Desktop, Mobile, and Tablet friendly. -Self-Paced Learning -No Time Limits or Expiration -Includes an evaluation and assessment -Downloadable Certificate -Credits are reported to CE Broker and/or CPE automatically within 24 hours
Topics Covered
Drugs for ADHD -Behavioral Therapies -Stimulants -Methylphenidate -Amphetamines -Dosing of Stimulants -Adverse Effects -Drug Interactions -Non stimulants -Alpha2-Agonists -Atomoxetine -Pregnancy and Lactation -Choice of Drugs -A Device Viloxazine ER (Qelbree) for ADHD -Standard Treatment -Mechanism of Action -Clinical Studies -Adverse Effects -Pregnancy and Lactation -Drug Interactions -Dosage and Administration Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD -Methylphenidate -Pharmacology -Clinical Studies -Adverse Effects -Pregnancy and Lactation -Drug Interactions -Dosage and Administration A New Amphetamine Oral Suspension (Adzenys ER) for ADHD -Stimulants -The New Formulation -Adverse Effects -Drug Interactions -Pregnancy and Lactation -Dosage and Administration Cotempla XR-ODT – Another Long-Acting Methylphenidate for ADHD -Methylphenidate -The New Formulation -Clinical Studies -Adverse Effects -Dosage and Administration
Learning Objectives
Upon completion of this activity, the participant will be able to: 1. Explain the current approach to the management of a patient withattention deficitt/hyperactivity disorder. 2. Discuss the drugs available for treatment ofattention deficitt/hyperactivity disorder and compare them based on their efficacy, dosage and administration, and potential adverse effects. 3. Review the efficacy and safety of viloxazine extended-release capsules (Qelbree), serdexmethylphenidate/dexmethylphenidate (Azstarys), amphetamine (Adzenys ER – Neos), and methylphenidate (Cotempla XR-ODT – Neos Therapeutics) for treatment of ADHD. 4. Determine the most appropriate therapy given the clinical presentation of an individual patient withattention deficitt/hyperactivity disorder.
Target Audience
Physicians Physicians Assistant
Additional credit info
This CME activity was planned and produced in accordance with the ACCME Essentials and Policies through the joint providership of The Medical Letter and AchieveCE. The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Medical Letter ® designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.